Azarova, A. M., Gautam, G., & George, R. E. (2011). Emerging importance of ALK in neuroblastoma. Seminars in Cancer Biology, 21(4), 267–275. https://doi.org/10.1016/j.semcancer.2011.09.005
Beierle, E. A. (n.d.). MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK). Frontiers in Bioscience (Elite Edition), 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/
Bell, E., Chen, L., Liu, T., Marshall, G. M., Lunec, J., & Tweddle, D. A. (2010). MYCN oncoprotein targets and their therapeutic potential. Cancer Letters, 293(2), 144–157. https://doi.org/10.1016/j.canlet.2010.01.015
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., Radlwimmer, B., Højfeldt, J. W., Truffaux, N., Castel, D., Schubert, S., Ryzhova, M., Şeker-Cin, H., Gronych, J., Johann, P. D., … Pfister, S. M. (2013). Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 24(5), 660–672. https://doi.org/10.1016/j.ccr.2013.10.006
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., Ahmad, Z., Barker, K., Moreau, L., Webber, H., Wang, W., Liu, Q., Perez-Atayde, A., Rodig, S., Cheung, N.-K., … George, R. E. (2012). The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer Cell, 22(1), 117–130. https://doi.org/10.1016/j.ccr.2012.06.001
Bleggi-Torres, L. F., de Noronha, L., Schneider Gugelmin, E., Martins Sebastião, A. P., Werner, B., Marques Maggio, E., Queiroz Telles, J. E., & Martins Collaço, L. (2001). Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system. Diagnostic Cytopathology, 24(4), 293–295. https://doi.org/10.1002/dc.1062
Blümcke, I., Aronica, E., Becker, A., Capper, D., Coras, R., Honavar, M., Jacques, T. S., Kobow, K., Miyata, H., Mühlebner, A., Pimentel, J., Söylemezoğlu, F., & Thom, M. (2016). Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification. Nature Reviews Neurology, 12(12), 732–740. https://doi.org/10.1038/nrneurol.2016.173
Brodeur, G. M. (2003). Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer, 3(3), 203–216. https://doi.org/10.1038/nrc1014
Brodeur, G. M., & Bagatell, R. (2014). Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 11(12), 704–713. https://doi.org/10.1038/nrclinonc.2014.168
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S. J., Wang, X., Harshbarger, T. L., D’Apuzzo, M., Ressler, J. A., Jensen, M. C., Barish, M. E., Chen, M., … Badie, B. (2016). Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine, 375(26), 2561–2569. https://doi.org/10.1056/NEJMoa1610497
Buckner, T., Blatt, J., & Smith, S. V. (2006). The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience. Pediatric and Developmental Pathology, 9(5), 374–380. https://doi.org/10.2350/06-02-0047.1
Burkhart, C. A., Cheng, A. J., Madafiglio, J., Kavallaris, M., Mili, M., Marshall, G. M., Weiss, W. A., Khachigian, L. M., Norris, M. D., & Haber, M. (2003). Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. JNCI Journal of the National Cancer Institute, 95(18), 1394–1403. https://doi.org/10.1093/jnci/djg045
Chen, L., Iraci, N., Gherardi, S., Gamble, L. D., Wood, K. M., Perini, G., Lunec, J., & Tweddle, D. A. (2010). p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. Cancer Research, 70(4), 1377–1388. https://doi.org/10.1158/0008-5472.CAN-09-2598
Chhabda, S., Carney, O., D’Arco, F., Jacques, T. S., & Mankad, K. (2016). The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. Quantitative Imaging in Medicine and Surgery, 6(5), 486–489. https://doi.org/10.21037/qims.2016.10.01
Children’s cancer statistics | Cancer Research UK. (n.d.). http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers
Cossu, I., Bottoni, G., Loi, M., Emionite, L., Bartolini, A., Di Paolo, D., Brignole, C., Piaggio, F., Perri, P., Sacchi, A., Curnis, F., Gagliani, M. C., Bruno, S., Marini, C., Gori, A., Longhi, R., Murgia, D., Sementa, A. R., Cilli, M., … Pastorino, F. (2015). Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. Biomaterials, 68, 89–99. https://doi.org/10.1016/j.biomaterials.2015.07.054
Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C. (2005). β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957. https://doi.org/10.1200/JCO.2005.01.5479
Evans, A. E., Baum, E., & Chard, R. (1981). Do infants with stage IV-S neuroblastoma need treatment? Archives of Disease in Childhood, 56(4), 271–274. https://doi.org/10.1136/adc.56.4.271
Fisher, J., Abramowski, P., Wisidagamage Don, N. D., Flutter, B., Capsomidis, A., Cheung, G. W.-K., Gustafsson, K., & Anderson, J. (2017). Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. Molecular Therapy, 25(5), 1234–1247. https://doi.org/10.1016/j.ymthe.2017.03.002
Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. (1984). Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage. Science, 224(4653), 1121–1124. http://www.jstor.org/stable/1692440
Ghorashian, S., Amrolia, P., & Veys, P. (2018). Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. Experimental Hematology, 66, 5–16. https://doi.org/10.1016/j.exphem.2018.07.002
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., Finkelstein, D., Pounds, S., Weiss, A., Patay, Z., Scoggins, M., Ogg, R., Pei, Y., Yang, Z.-J., Brun, S., … Gilbertson, R. J. (2010). Subtypes of medulloblastoma have distinct developmental origins. Nature, 468(7327), 1095–1099. https://doi.org/10.1038/nature09587
Goschzik, T., Gessi, M., Dreschmann, V., Gebhardt, U., Wang, L., Yamaguchi, S., Wheeler, D. A., Lauriola, L., Lau, C. C., Müller, H. L., & Pietsch, T. (2017). Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlw116
Greaves, M. F., & Wiemels, J. (2003). Origins of chromosome translocations in childhood leukaemia. Nature Reviews Cancer, 3(9), 639–649. https://doi.org/10.1038/nrc1164
Guglielmi, L., Cinnella, C., Nardella, M., Maresca, G., Valentini, A., Mercanti, D., Felsani, A., & D’Agnano, I. (2014). MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death & Disease, 5(2), e1081–e1081. https://doi.org/10.1038/cddis.2014.42
Gump, J. M., Donson, A. M., Birks, D. K., Amani, V. M., Rao, K. K., Griesinger, A. M., Kleinschmidt-DeMasters, B. K., Johnston, J. M., Anderson, R. C. E., Rosenfeld, A., Handler, M., Gore, L., Foreman, N., & Hankinson, T. C. (2015). Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathologica Communications, 3(1). https://doi.org/10.1186/s40478-015-0211-5
Hanahan, D., & Weinberg, R. A. (2000). The Hallmarks of Cancer. Cell, 100(1), 57–70. https://doi.org/10.1016/S0092-8674(00)81683-9
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., Solomon, D., Mueller, S., Paris, P. L., Zhang, Z., Petritsch, C., Gupta, N., Waldman, T. A., & James, C. D. (2014). Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine, 20(12), 1394–1396. https://doi.org/10.1038/nm.3716
Hasle, H., & Niemeyer, C. M. (2011). Advances in the prognostication and management of advanced MDS in children. British Journal of Haematology, 154(2), 185–195. https://doi.org/10.1111/j.1365-2141.2011.08724.x
Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., Ryan, S. L., Poon, E., Robinson, S. P., Ruddle, R., Raynaud, F. I., Howell, L., Kwok, C., Joshi, A., Nicholson, S. L., … Clifford, S. C. (2015). Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 27(1), 72–84. https://doi.org/10.1016/j.ccell.2014.11.002
Hourigan, C. S., & Karp, J. E. (2013). Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology, 10(8), 460–471. https://doi.org/10.1038/nrclinonc.2013.100
Huang, M., & Weiss, W. A. (2013). Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 3(10), a014415–a014415. https://doi.org/10.1101/cshperspect.a014415
Huber, K., Kalcheim, C., & Unsicker, K. (2009). The development of the chromaffin cell lineage from the neural crest. Autonomic Neuroscience, 151(1), 10–16. https://doi.org/10.1016/j.autneu.2009.07.020
Hubert, C. G., Rivera, M., Spangler, L. C., Wu, Q., Mack, S. C., Prager, B. C., Couce, M., McLendon, R. E., Sloan, A. E., & Rich, J. N. (2016). A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found. Cancer Research, 76(8), 2465–2477. https://doi.org/10.1158/0008-5472.CAN-15-2402
Hunger, S. P., & Mullighan, C. G. (2015). Acute Lymphoblastic Leukemia in Children. New England Journal of Medicine, 373(16), 1541–1552. https://doi.org/10.1056/NEJMra1400972
International Agency for Research on Cancer. (2016). WHO classification of tumours of the central nervous system (D. N. Louis, H. Ohgaki, O. D. Wiestler, & W. K. Cavenee, Eds.; Revised 4th edition). International Agency for Research on Cancer.
Johnson, L. A., & June, C. H. (2017). Driving gene-engineered T cell immunotherapy of cancer. Cell Research, 27(1), 38–58. https://doi.org/10.1038/cr.2016.154
Kirsti Sirkiä, Ulla M. Saarinen‐Pihkala, Liisa Hovi, Hannu Sariola. (1998). Autopsy in children with cancer who die while in terminal care. Medical and Pediatric Oncology, 30(5), 284–289. https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016). Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 22(1), 26–36. https://doi.org/10.1038/nm.4015
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903–907. https://doi.org/10.1038/nature06309
Korshunov, AndreySturm, DominikRyzhova, MarinaHovestadt, VolkerGessi, Marco. (n.d.). Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 128(8), 279–289. https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&accountid=14511
Kotrova, M., Trka, J., Kneba, M., & Brüggemann, M. (2017). Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? Molecular Diagnosis & Therapy, 21(5), 481–492. https://doi.org/10.1007/s40291-017-0277-9
Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., Xu, R., Zhu, X., Zhang, J., Russell, H. R., Peters, J. L., Finkelstein, D., Xu, B., Lin, T., Tinkle, C. L., … Baker, S. J. (2018). Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.11.015
Lee, T. I., & Young, R. A. (2013). Transcriptional Regulation and Its Misregulation in Disease. Cell, 152(6), 1237–1251. https://doi.org/10.1016/j.cell.2013.02.014
Lewis, P. W., Muller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013). Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. Science, 340(6134), 857–861. https://doi.org/10.1126/science.1232245
Liu, Z., & Thiele, C. J. (2012). ALK and MYCN: When Two Oncogenes Are Better than One. Cancer Cell, 21(3), 325–326. https://doi.org/10.1016/j.ccr.2012.03.004
Lord, C. J., & Ashworth, A. (2010). Biology-driven cancer drug development: back to the future. BMC Biology, 8(1). https://doi.org/10.1186/1741-7007-8-38
Lu, B., Green, B., Farr, J., Lopes, F., & Van Raay, T. (2016). Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. Cancers, 8(9). https://doi.org/10.3390/cancers8090082
Mackall, C. L., Merchant, M. S., & Fry, T. J. (2014). Immune-based therapies for childhood cancer. Nature Reviews Clinical Oncology, 11(12), 693–703. https://doi.org/10.1038/nrclinonc.2014.177
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017). Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell, 31(4), 476–485. https://doi.org/10.1016/j.ccell.2017.03.002
Marabelle, A., Sapin, V., Rousseau, R., Periquet, B., Demeocq, F., & Kanold, J. (2009). Hypercalcemia and 13- -retinoic acid in post-consolidation therapy of neuroblastoma. Pediatric Blood & Cancer, 52(2), 280–283. https://doi.org/10.1002/pbc.21768
Martinez-Barbera, J. P., & Andoniadou, C. L. (2016). Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. STEM CELLS, 34(2), 268–276. https://doi.org/10.1002/stem.2267
Martinez-Barbera, J. P., & Buslei, R. (2015). Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models. Journal of Pediatric Endocrinology and Metabolism, 28(1–2). https://doi.org/10.1515/jpem-2014-0442
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., & Reynolds, C. P. (1999). Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13- -Retinoic Acid. New England Journal of Medicine, 341(16), 1165–1173. https://doi.org/10.1056/NEJM199910143411601
Milne, T. A. (2017). Mouse models of MLL leukemia: recapitulating the human disease. Blood, 129(16), 2217–2223. https://doi.org/10.1182/blood-2016-10-691428
Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell, 164(4), 780–791. https://doi.org/10.1016/j.cell.2016.01.012
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N. J., Brodeur, G. M., Tonini, G. P., … Maris, J. M. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 455(7215), 930–935. https://doi.org/10.1038/nature07261
Nataliya Zhukova. (2013). Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 31(23). https://doi.org/10.1200/JCO.2012.48.5052
Nature Reviews Immunology. (2012). 12(4). https://www.nature.com/nri/volumes/12/issues/4
Niemeyer, C. M., & Kratz, C. P. (2008). Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. British Journal of Haematology, 140(6), 610–624. https://doi.org/10.1111/j.1365-2141.2007.06958.x
Niklison-Chirou, M. V., Erngren, I., Engskog, M., Haglöf, J., Picard, D., Remke, M., McPolin, P. H. R., Selby, M., Williamson, D., Clifford, S. C., Michod, D., Hadjiandreou, M., Arvidsson, T., Pettersson, C., Melino, G., & Marino, S. (2017). TAp73 is a marker of glutamine addiction in medulloblastoma. Genes & Development, 31(17), 1738–1753. https://doi.org/10.1101/gad.302349.117
Northcott, P. A., Korshunov, A., Pfister, S. M., & Taylor, M. D. (2012). The clinical implications of medulloblastoma subgroups. Nature Reviews Neurology, 8(6), 340–351. https://doi.org/10.1038/nrneurol.2012.78
O’Connor, D., Enshaei, A., Bartram, J., Hancock, J., Harrison, C. J., Hough, R., Samarasinghe, S., Schwab, C., Vora, A., Wade, R., Moppett, J., Moorman, A. V., & Goulden, N. (2018a). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 36(1), 34–43. https://doi.org/10.1200/JCO.2017.74.0449
O’Connor, D., Enshaei, A., Bartram, J., Hancock, J., Harrison, C. J., Hough, R., Samarasinghe, S., Schwab, C., Vora, A., Wade, R., Moppett, J., Moorman, A. V., & Goulden, N. (2018b). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 36(1), 34–43. https://doi.org/10.1200/JCO.2017.74.0449
Pastorino, F., Marimpietri, D., Brignole, C., Paolo, D., Pagnan, G., Daga, A., Piccardi, F., Cilli, M., Allen, T., & Ponzoni, M. (2007). Ligand-Targeted Liposomal Therapies of Neuroblastoma. Current Medicinal Chemistry, 14(29), 3070–3078. https://doi.org/10.2174/092986707782793916
Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A. S., Nitarska, J., Pahlavan, P., Henderson, S., Mikael, L. G., Richard-Londt, A., Zhang, Y., Costa, J. R., Hébert, S., Khazaei, S., Ibrahim, N. S., Herrero, J., Riccio, A., Albrecht, S., Ketteler, R., Brandner, S., … Salomoni, P. (2017). H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell, 32(5), 684-700.e9. https://doi.org/10.1016/j.ccell.2017.09.014
Pfister, S., Remke, M., Castoldi, M., Bai, A. H. C., Muckenthaler, M. U., Kulozik, A., von Deimling, A., Pscherer, A., Lichter, P., & Korshunov, A. (2009). Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathologica, 117(4), 457–464. https://doi.org/10.1007/s00401-008-0467-y
Phoenix, T. N., Patmore, D. M., Boop, S., Boulos, N., Jacus, M. O., Patel, Y. T., Roussel, M. F., Finkelstein, D., Goumnerova, L., Perreault, S., Wadhwa, E., Cho, Y.-J., Stewart, C. F., & Gilbertson, R. J. (2016). Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell, 29(4), 508–522. https://doi.org/10.1016/j.ccell.2016.03.002
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., Ghorashian, S., Pinner, D., Ahsan, G., Gilmour, K., Lucchini, G., Inglott, S., Mifsud, W., Chiesa, R., Peggs, K. S., … Veys, P. (2017). Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science Translational Medicine, 9(374). https://doi.org/10.1126/scitranslmed.aaj2013
Qiao, J., Paul, P., Lee, S., Qiao, L., Josifi, E., Tiao, J. R., & Chung, D. H. (2012). PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochemical and Biophysical Research Communications, 424(3), 421–426. https://doi.org/10.1016/j.bbrc.2012.06.125
Rasaiyaah, J., Georgiadis, C., Preece, R., Mock, U., & Qasim, W. (2018). TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight, 3(13). https://doi.org/10.1172/jci.insight.99442
Reynolds, C. P., Matthay, K. K., Villablanca, J. G., & Maurer, B. J. (2003). Retinoid therapy of high-risk neuroblastoma. Cancer Letters, 197(1–2), 185–192. https://doi.org/10.1016/S0304-3835(03)00108-3
Richmond, A., & Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer therapeutics. Disease Models and Mechanisms, 1(2–3), 78–82. https://doi.org/10.1242/dmm.000976
Sadelain, M., Rivière, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423–431. https://doi.org/10.1038/nature22395
Schwab, M. (2004). MYCN in neuronal tumours. Cancer Letters, 204(2), 179–187. https://doi.org/10.1016/S0304-3835(03)00454-3
Schwalbe, E. C., Lindsey, J. C., Nakjang, S., Crosier, S., Smith, A. J., Hicks, D., Rafiee, G., Hill, R. M., Iliasova, A., Stone, T., Pizer, B., Michalski, A., Joshi, A., Wharton, S. B., Jacques, T. S., Bailey, S., Williamson, D., & Clifford, S. C. (2017). Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. The Lancet Oncology, 18(7), 958–971. https://doi.org/10.1016/S1470-2045(17)30243-7
Schwalbe, Ed. C., Hayden, J. T., Rogers, H. A., Miller, S., Lindsey, J. C., Hill, R. M., Nicholson, S.-L., Kilday, J.-P., Adamowicz-Brice, M., Storer, L., Jacques, T. S., Robson, K., Lowe, J., Williamson, D., Grundy, R. G., Bailey, S., & Clifford, S. C. (2013). Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathologica, 126(6), 943–946. https://doi.org/10.1007/s00401-013-1206-6
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., … Collins, V. P. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 482(7384), 226–231. https://doi.org/10.1038/nature10833
Sidell, N. (1982). Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/68.4.589
Slany, R. K. (2016). The molecular mechanics of mixed lineage leukemia. Oncogene, 35(40), 5215–5223. https://doi.org/10.1038/onc.2016.30
Stone, T. J., & Jacques, T. S. (2015). Medulloblastoma: selecting children for reduced treatment. Neuropathology and Applied Neurobiology, 41(2), 106–108. https://doi.org/10.1111/nan.12193
Strebhardt, K., & Ullrich, A. (2008). Paul Ehrlich’s magic bullet concept: 100 years of progress. Nature Reviews Cancer, 8(6), 473–480. https://doi.org/10.1038/nrc2394
Sturm, D., Orr, B. A., Toprak, U. H., Hovestadt, V., Jones, D. T. W., Capper, D., Sill, M., Buchhalter, I., Northcott, P. A., Leis, I., Ryzhova, M., Koelsche, C., Pfaff, E., Allen, S. J., Balasubramanian, G., Worst, B. C., Pajtler, K. W., Brabetz, S., Johann, P. D., … Schniederjan, M. J. (2016). New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 164(5), 1060–1072. https://doi.org/10.1016/j.cell.2016.01.015
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., Kool, M., Zapatka, M., Becker, N., Zucknick, M., Hielscher, T., Liu, X.-Y., Fontebasso, A. M., Ryzhova, M., Albrecht, S., … Witt, O. (2012). Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 22(4), 425–437. https://doi.org/10.1016/j.ccr.2012.08.024
Taylor, Michael DNorthcott, Paul AKorshunov, AndreyRemke, MarcCho, Yoon-jae. (n.d.). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(3), 465–472. https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013a). Cancer Genome Landscapes. Science, 339(6127), 1546–1558. https://doi.org/10.1126/science.1235122
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013b). Cancer Genome Landscapes. Science, 339(6127), 1546–1558. https://doi.org/10.1126/science.1235122
Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., Moorman, A. V., & Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. The Lancet Oncology, 15(8), 809–818. https://doi.org/10.1016/S1470-2045(14)70243-8
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013). Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. The Lancet Oncology, 14(3), 199–209. https://doi.org/10.1016/S1470-2045(12)70600-9
Wegman-Ostrosky, T., & Savage, S. A. (2017). The genomics of inherited bone marrow failure: from mechanism to the clinic. British Journal of Haematology, 177(4), 526–542. https://doi.org/10.1111/bjh.14535
Weinberg, R. A. (2014). The biology of cancer (2nd ed). Garland Science.
Wright, J. H. (1910). NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED. The Journal of Experimental Medicine, 12(4). https://doi.org/10.1084/jem.12.4.556
Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. (n.d.). PHOX2B Is Associated with Neuroblastoma Cell Differentiation. Cancer Biotherapy & Radiopharmaceuticals, 31, 44–51. https://doi.org/10.1089/cbr.2015.1952
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017). CAR T-cell therapy of solid tumors. Immunology and Cell Biology, 95(4), 356–363. https://doi.org/10.1038/icb.2016.128
Zelent, A., Greaves, M., & Enver, T. (2004). Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene, 23(24), 4275–4283. https://doi.org/10.1038/sj.onc.1207672
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., Stewart, R. A., Wang, W., George, R. E., Kanki, J. P., & Look, A. T. (2012). Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. Cancer Cell, 21(3), 362–373. https://doi.org/10.1016/j.ccr.2012.02.010
